Angiocrine Bioscience is a private, clinical-stage cell and gene therapy company harnessing the power of genetically modified human endothelial cells to regenerate tissues, restore function and rejuvenate patients with serious medical conditions.

Biotechnology

Angiocrine Bioscience

Paul Finnegan

Kathy K. Park

Gayle Bresnahan

Doreen G.

Geoff Davis

Margie Breneman

John R. Jaskowiak

Lee Landeen

John Lomoro

John K. Fraser

Daniel J. Nolan

Michael Ginsberg

The Research and Development team at Angiocrine Bioscience is dedicated to advancing innovative cell and gene therapies by designing and conducting experiments to evaluate the efficacy and safety of genetically modified endothelial cells. This multidisciplinary team collaborates on product development, external research partnerships, and bioprocess engineering, ensuring the successful translation of scientific discoveries into clinical applications to improve patient outcomes.

Research and Development

Executive Administration

Leadership Team

Advisory Team

Research and Development

About

Team members

Other teams at Angiocrine Bioscience

Executive Administration

Leadership Team

Advisory Team